J&J seeks FDA green light for new use of Nucynta XR tablets; Depomed reports $8.6M loss in 3Q;

> West ($WST), a maker of products for injected drugs, has teamed up drug-delivery specialist Vetter to make filled Daikyo Crystal Zenith syringes. Release

> Johnson & Johnson ($JNJ) has asked the FDA to approved its extended-release Nucynta (tapentadol) tablets for pain from diabetic peripheral neuropathy. Release

> Depomed ($DEPO), a developer and provider of extended-release drugs, reported a net loss of $8.6 million in the third quarter, compared with net income of $1.9 million for the same period last year. Release

> Oxford Pharmascience, a developer of new formulations of generic drugs, has raised more than £1.1 million to fund its programs and its business in Brazil. Article

> Halozyme ($HALO) provided upbeat data from an early trial of its fast-acting drug tech used with insulin in patients with type 1 diabetes. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.